Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 65990 | 5 |
09:34 ET | 17703 | 5.0657 |
09:36 ET | 13721 | 5.04 |
09:38 ET | 68457 | 5.02 |
09:39 ET | 10447 | 5.005 |
09:41 ET | 6175 | 5.02 |
09:43 ET | 5501 | 5.015 |
09:45 ET | 5921 | 5 |
09:48 ET | 10447 | 5.02 |
09:50 ET | 6080 | 5.06 |
09:52 ET | 19349 | 5.075 |
09:54 ET | 12274 | 5.08 |
09:56 ET | 4463 | 5.0699 |
09:57 ET | 9442 | 5.07 |
09:59 ET | 41324 | 5.109 |
10:01 ET | 20156 | 5.07 |
10:03 ET | 6000 | 5.03 |
10:06 ET | 5841 | 5.05 |
10:08 ET | 5411 | 5.0545 |
10:10 ET | 9156 | 5.045 |
10:12 ET | 5921 | 5.03 |
10:14 ET | 5480 | 5.04 |
10:15 ET | 22589 | 5.025 |
10:17 ET | 4287 | 5.035 |
10:19 ET | 16486 | 4.995 |
10:21 ET | 2706 | 4.995 |
10:24 ET | 3339 | 5.015 |
10:26 ET | 7908 | 4.975 |
10:28 ET | 20216 | 4.915 |
10:30 ET | 6300 | 4.9 |
10:32 ET | 9437 | 4.92 |
10:33 ET | 6899 | 4.95 |
10:35 ET | 6706 | 4.972 |
10:37 ET | 2538 | 4.95 |
10:39 ET | 8638 | 4.965 |
10:42 ET | 10329 | 4.945 |
10:44 ET | 4094 | 4.9775 |
10:46 ET | 2929 | 4.95 |
10:48 ET | 4316 | 4.99 |
10:50 ET | 3890 | 5.015 |
10:51 ET | 14455 | 5 |
10:53 ET | 3970 | 5.01 |
10:55 ET | 4706 | 4.985 |
10:57 ET | 3250 | 4.9849 |
11:00 ET | 5711 | 4.99 |
11:02 ET | 10513 | 4.95 |
11:04 ET | 3512 | 4.965 |
11:06 ET | 3673 | 4.95 |
11:08 ET | 5164 | 4.935 |
11:09 ET | 4128 | 4.935 |
11:11 ET | 8542 | 4.93 |
11:13 ET | 2649 | 4.91 |
11:15 ET | 15739 | 4.88 |
11:18 ET | 6211 | 4.89 |
11:20 ET | 4152 | 4.89 |
11:22 ET | 5997 | 4.9 |
11:24 ET | 700 | 4.9 |
11:26 ET | 6878 | 4.885 |
11:27 ET | 3743 | 4.88 |
11:29 ET | 3752 | 4.885 |
11:31 ET | 12097 | 4.845 |
11:33 ET | 4543 | 4.85 |
11:36 ET | 12099 | 4.83 |
11:38 ET | 5712 | 4.83 |
11:40 ET | 5126 | 4.85 |
11:42 ET | 984 | 4.845 |
11:44 ET | 1000 | 4.845 |
11:45 ET | 3580 | 4.835 |
11:47 ET | 4120 | 4.84 |
11:49 ET | 2600 | 4.875 |
11:51 ET | 5267 | 4.89 |
11:54 ET | 2131 | 4.89 |
11:56 ET | 2606 | 4.9 |
11:58 ET | 2580 | 4.91 |
12:00 ET | 5225 | 4.9 |
12:02 ET | 7282 | 4.9 |
12:03 ET | 1396 | 4.9027 |
12:05 ET | 2157 | 4.895 |
12:07 ET | 8581 | 4.835 |
12:09 ET | 7803 | 4.855 |
12:12 ET | 5272 | 4.84 |
12:14 ET | 3227 | 4.84 |
12:16 ET | 5052 | 4.84 |
12:18 ET | 10089 | 4.8398 |
12:20 ET | 2520 | 4.815 |
12:21 ET | 5808 | 4.811 |
12:23 ET | 10426 | 4.805 |
12:25 ET | 3503 | 4.81 |
12:27 ET | 964 | 4.805 |
12:30 ET | 22076 | 4.75 |
12:32 ET | 4476 | 4.79 |
12:34 ET | 700 | 4.785 |
12:36 ET | 6183 | 4.805 |
12:38 ET | 20114 | 4.815 |
12:39 ET | 4775 | 4.8 |
12:41 ET | 4433 | 4.815 |
12:43 ET | 1400 | 4.8199 |
12:45 ET | 3875 | 4.77 |
12:48 ET | 4613 | 4.785 |
12:50 ET | 418 | 4.775 |
12:54 ET | 4877 | 4.79 |
12:56 ET | 200 | 4.8 |
12:59 ET | 616 | 4.8 |
01:01 ET | 2411 | 4.79 |
01:03 ET | 100 | 4.79 |
01:06 ET | 2959 | 4.795 |
01:08 ET | 3609 | 4.795 |
01:10 ET | 1138 | 4.785 |
01:12 ET | 1925 | 4.79 |
01:14 ET | 1100 | 4.795 |
01:15 ET | 8120 | 4.79 |
01:17 ET | 200 | 4.785 |
01:19 ET | 2485 | 4.795 |
01:21 ET | 2590 | 4.79 |
01:24 ET | 1500 | 4.785 |
01:26 ET | 2355 | 4.78 |
01:28 ET | 791 | 4.7851 |
01:30 ET | 5126 | 4.805 |
01:32 ET | 300 | 4.81 |
01:33 ET | 35833 | 4.795 |
01:35 ET | 1200 | 4.795 |
01:37 ET | 400 | 4.79 |
01:39 ET | 1908 | 4.79 |
01:42 ET | 3285 | 4.76 |
01:44 ET | 3177 | 4.76 |
01:46 ET | 3746 | 4.79 |
01:48 ET | 2581 | 4.79 |
01:51 ET | 1352 | 4.7827 |
01:53 ET | 500 | 4.785 |
01:55 ET | 400 | 4.78 |
01:57 ET | 900 | 4.78 |
02:00 ET | 500 | 4.78 |
02:02 ET | 9530 | 4.775 |
02:04 ET | 4224 | 4.775 |
02:06 ET | 1007 | 4.77 |
02:08 ET | 400 | 4.76 |
02:09 ET | 5530 | 4.775 |
02:11 ET | 1600 | 4.78 |
02:13 ET | 415 | 4.79 |
02:15 ET | 200 | 4.785 |
02:18 ET | 3378 | 4.785 |
02:20 ET | 100 | 4.79 |
02:22 ET | 400 | 4.78 |
02:24 ET | 7184 | 4.765 |
02:26 ET | 861 | 4.76 |
02:27 ET | 400 | 4.76 |
02:29 ET | 700 | 4.76 |
02:31 ET | 3621 | 4.785 |
02:33 ET | 600 | 4.785 |
02:36 ET | 400 | 4.785 |
02:38 ET | 577 | 4.785 |
02:40 ET | 2558 | 4.78 |
02:42 ET | 2479 | 4.785 |
02:45 ET | 3673 | 4.775 |
02:47 ET | 6080 | 4.77 |
02:49 ET | 10941 | 4.76 |
02:51 ET | 14896 | 4.73 |
02:54 ET | 400 | 4.73 |
02:56 ET | 840 | 4.73 |
02:58 ET | 3452 | 4.74 |
03:00 ET | 253 | 4.745 |
03:02 ET | 5898 | 4.765 |
03:03 ET | 5116 | 4.75 |
03:05 ET | 200 | 4.745 |
03:07 ET | 1018 | 4.745 |
03:09 ET | 2723 | 4.7425 |
03:12 ET | 3033 | 4.74 |
03:14 ET | 2070 | 4.735 |
03:16 ET | 1896 | 4.745 |
03:18 ET | 800 | 4.75 |
03:20 ET | 1179 | 4.745 |
03:21 ET | 7091 | 4.745 |
03:23 ET | 1244 | 4.735 |
03:25 ET | 3146 | 4.7424 |
03:27 ET | 400 | 4.75 |
03:30 ET | 900 | 4.745 |
03:32 ET | 14865 | 4.72 |
03:34 ET | 3663 | 4.73 |
03:36 ET | 1916 | 4.7275 |
03:38 ET | 4206 | 4.715 |
03:39 ET | 8199 | 4.715 |
03:41 ET | 6038 | 4.74 |
03:43 ET | 3917 | 4.745 |
03:45 ET | 13444 | 4.755 |
03:48 ET | 4450 | 4.75 |
03:50 ET | 8279 | 4.75 |
03:52 ET | 9218 | 4.77 |
03:54 ET | 15858 | 4.745 |
03:56 ET | 8562 | 4.74 |
03:57 ET | 57521 | 4.7 |
03:59 ET | 69296 | 4.685 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 3.4B | -3.0x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Xenon Pharmaceuticals Inc | 3.1B | -15.0x | --- |
Iovance Biotherapeutics Inc | 3.0B | -5.9x | --- |
SpringWorks Therapeutics Inc | 3.1B | -8.3x | --- |
Biohaven Ltd | 3.0B | -5.4x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.26 |
EPS | $-1.54 |
Book Value | $0.11 |
P/E Ratio | -3.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.